Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zealand Pharma A/S

http://www.zealandpharma.com/

Latest From Zealand Pharma A/S

Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry

Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?

Business Strategies Clinical Trials

EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Clinical Trials Liver & Hepatic

Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data

Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue

Clinical Trials Metabolic Disorders

Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval

The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval. 

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Encycle Therapeutics, Inc.
    • Valeritas Holdings, Inc.
UsernamePublicRestriction

Register